Treatment of symptomatic osteoporosis in children: A comparison of two pamidronate dosage regimens

Journal of Pediatric Endocrinology and Metabolism

Volumn 24, Issue 5-6, 2011, Pages 271-274

  Martinez Soto, Tania ^a   Pacaud, Danièle ^a   Stephure, David ^a   Trussell, Rebecca ^a   Huang, Carol ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

children; fractures; osteoporosis; pamidronate

Indexed keywords

CALCIUM; PAMIDRONIC ACID; VITAMIN D;

ADOLESCENT; ADULT; ARTICLE; BONE DENSITY; BONE FRAGILITY; BONE NECROSIS; CLINICAL ARTICLE; DESCRIPTIVE RESEARCH; DRUG DOSE COMPARISON; DRUG EFFICACY; HUMAN; MULTIPLE CYCLE TREATMENT; OSTEOGENESIS IMPERFECTA; OSTEOPOROSIS; RETROSPECTIVE STUDY; THERAPY EFFECT; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CHILD; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FRACTURES, BONE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; OSTEOPOROSIS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 79959473132     PISSN: 0334018X     EISSN: 0334018X     Source Type: Journal    
DOI: 10.1515/JPEM.2011.182     Document Type: Article

References (13)

1. Ward L, Tricco AC, Phuong P, Cranney A, Barrowman N, et al. Bisphosphonate therapy for children and adolescents with secondary osteoporosis. Cochrane Database Syst Rev 2007;CD005324.
2. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, et al. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998;339:947-52. (Pubitemid 28455096)
3. Speiser PW, Clarson CL, Eugster EA, Kemp SF, Radovick S, et al. Bisphosphonate treatment of pediatric bone disease. Pediatr Endocrinol Rev 2005;3:87-96. (Pubitemid 43213211)
4. Gandrud LM, Cheung JC, Daniels MW, Bachrach LK. Low-dose intravenous pamidronate reduces fractures in childhood osteoporosis. J Pediatr Endocrinol Metab 2003;16:887-92. (Pubitemid 37259176)
5. Steelman J, Zeitler P. Treatment of symptomatic pediatric osteoporosis with cyclic single-day intravenous pamidronate infusions. J Pediatr 2003;142:417-23. (Pubitemid 36521229)
6. Plotkin H, Coughlin S, Kreikemeier R, Heldt K, Bruzoni M, et al. Low doses of pamidronate to treat osteopenia in children with severe cerebral palsy: a pilot study. Dev Med Child Neurol 2006;48:709-12. (Pubitemid 44227159)
7. Bachrach SJ, Kecskemethy HH, Harcke HT, Lark RK, Miller F, et al. Pamidronate treatment and posttreatment bone density in children with spastic quadriplegic cerebral palsy. J Clin Densitom 2006;9:167-74. (Pubitemid 43903289)
8. Bachrach LK, Ward LM. Clinical review 1: Bisphosphonate use in childhood osteoporosis. J Clin Endocrinol Metab 2009;94:400-9.
9. Bachrach LK, Hastie T, Wang MC, Narasimhan B, Marcus R. Bone mineral acquisition in healthy Asian, Hispanic, black, and Caucasian youth: a longitudinal study. J Clin Endocrinol Metab 1999;84:4702-12.
10. Ward KA, Adams JE, Freemont TJ, Mughal MZ. Can bispho-sphonate treatment be stopped in a growing child with skeletal fragility? Osteoporos Int 2007;18:1137-40. (Pubitemid 47019997)
11. Gordon CM, Bachrach LK, Carpenter TO, Crabtree N, El-Hajj Fuleihan G, et al. Dual energy X-ray absorptiometry inter pretation and reporting in children and adolescents: The 2007 ISCD Pediatric Official Positions. J Clin Densitom 2008;11:43-58. (Pubitemid 351602187)
12. Rauch F, Munns C, Land C, Glorieux FH. Pamidronate in children and adolescents with osteogenesis imperfecta: effect of treatment discontinuation. J Clin Endocrinol Metab 2006;91:1268-74.
13. Andiran N, Alikasifoglu A, Gonc N, Ozon A, Kandemir N, et al. Cyclic pamidronate therapy in children with osteogenesis imper-fecta: results of treatment and follow-up after discontinuation. J Pediatr Endocrinol Metab 2008;21:63-72.